April 02, 2025

FDA Approves Automated Latent TB Test

Revvity’s Auto-Pure 2400 platform for use with the T-SPOT.TB test to automate latent tuberculosis diagnostics was approved by the FDA.

Conexiant

April 01, 2025

FDA Monthly Round-Up: Key March Updates

March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 27, 2025

Study Finds Significant Increases in Prevalence, Severity of Astigmatism

Prolonged digital device use and reduced outdoor exposure following the COVID-19 pandemic may have contributed to the refractive changes.

Conexiant

March 25, 2025

Most Pediatric Valve Implants Used Off-Label

Fewer than 10% of cardiac valve devices implanted in U.S. pediatric patients were FDA approved for children.

Conexiant

March 19, 2025

Study: Sex Differences in Physician Suicide

Researchers found that female physicians had a significantly higher suicide risk than female nonphysicians.

Conexiant

March 18, 2025

FDA Approves First Liquid Losartan Formulation

FDA approves Arbli (TM), the first ready-to-use losartan oral suspension for hypertension, stroke risk reduction, and diabetic nephropathy.

Conexiant

March 14, 2025

FDA Recommends Influenza Vaccine Strains for 2025 to 2026

The FDA has selected influenza vaccine strains for the 2025 to 2026 U.S. flu season, maintaining consistency with prior formulations while incorporating updated epidemiologic and antigenic data to optimize protection.

Conexiant

March 13, 2025

FDA Chief Counsel Resigns Two Days In

U.S. FDA's chief counsel resigns amidst controversy surrounding her appointment and connections to mifepristone during the Biden administration.

Reuters